American Association for Cancer Research

Skip to Main Content

Table 3

Occurrence of CIS or invasive cancer in patients with: MD (A), MD (B), and SD (C) at baseline biopsy

Patient	A. MD
Patient		D^a	No. of molecular abnormalities	Carcinoma^b	CIS^b	Total
1	1	0	0	0	0
2	1	3	0	0	0
3	1	0	0	0	0
4	1	1	1	0	1
5^c	2	1	0	1	1
6	1	0	0	0	0
7	1	2	0	0	0
8^c	1	0	1	0	1
9^c	1	2	0	1	1
10^c	1	3	0	1	1
11^c	1	2	1	0	1

Patient	A. MD
Patient		D^a	No. of molecular abnormalities	Carcinoma^b	CIS^b	Total
1	1	0	0	0	0
2	1	3	0	0	0
3	1	0	0	0	0
4	1	1	1	0	1
5^c	2	1	0	1	1
6	1	0	0	0	0
7	1	2	0	0	0
8^c	1	0	1	0	1
9^c	1	2	0	1	1
10^c	1	3	0	1	1
11^c	1	2	1	0	1

Patient	B. MD
Patient		D	No. of molecular abnormalities	Carcinoma	CIS	Total
1	1	3	0	0	0
2	1	1	0	0	0
3^c	2	0 and 3	0	1	1
4	1	3	1	0	1
5	2	2 and 2	0	0	0
6	1	1	1	0	1
7^c	1	3	0	1	1

Patient	B. MD
Patient		D	No. of molecular abnormalities	Carcinoma	CIS	Total
1	1	3	0	0	0
2	1	1	0	0	0
3^c	2	0 and 3	0	1	1
4	1	3	1	0	1
5	2	2 and 2	0	0	0
6	1	1	1	0	1
7^c	1	3	0	1	1

Patient	C. SD
Patient		D	No. of molecular abnormalities	Carcinoma	CIS	Total
1	1	3	1	0	1
2	1	3	0	0	0
3	1	4	0	1	1
4	1	1	0	0	0
5	1	3	0	1	1
6	1	3	0	0	0
7	1	2	1	1	2
8	1	3	0	1	1
9	1	3	0	1	1

Patient	C. SD
Patient		D	No. of molecular abnormalities	Carcinoma	CIS	Total
1	1	3	1	0	1
2	1	3	0	0	0
3	1	4	0	1	1
4	1	1	0	0	0
5	1	3	0	1	1
6	1	3	0	0	0
7	1	2	1	1	2
8	1	3	0	1	1
9	1	3	0	1	1

^a

Number of dysplastic area.

^b

Carcinoma and CIS are diagnosed additionally after baseline biopsy.

^c

Patients with another high-grade lesion.